08:00 | Registration |
|
Session: Emerging Technologies |
| |
09:00 |  | Keynote Presentation Targeted Gold Nanoparticles In Molecular Imaging and Therapy of Cancers
Kattesh V. Katti, Director, Institute of Green Nanotechnology / Radiology / Cancer Nanotechnology Platform, University of Missouri, United States of America
This presentation will include details on clinical utility of tumor cell specific Gold Nanoparticles as tumor specific molecular imaging (X ray CT and Photoacoustic) and therapy agents for molecular imaging and therapy of receptor positive human cancers. |
|
09:30 | Rapid, Ultrasensitive Biomolecular Detection in Unpurified Samples with Chip-based Sensors
Shana Kelley, Professor, University of Toronto, Canada
Our research group recently developed a microchip platform that exhibits detection of nucleic acids with sensitivity enabling the direct, PCR-free analysis of clinical samples. This platform has now been optimized further to detect oncogenes in cancer cells at remarkably low levels, and bacterial targets at clinically relevant concentrations. |
10:00 | Fully Automated Molecular Testing; Pre-commercial Evaluation of a Cassette Based System Versus Existing Methods for HSV
Nathalie Visomblin, Manager Assay Development, GenturaDx, United States of America
|
10:30 | Coffee & Networking in Exhibition Hall |
11:15 | From Gene Panels to Genomes: The Progression of Next Generation Sequencing into the Clinical Laboratory
Karl Voelkerding, Professor/Medical Director, The University of Utah, United States of America
This presentation will describe the translational landscape with respect to the ongoing introduction of next generation sequencing into the clinical laboratory. This rapidly evolving area poses both substantial opportunities and implementation challenges for clinical laboratories. |
11:45 | Portable and Handheld TIRF Sensors for Accurate and Rapid Molecular Diagnostics
Alexander Asanov, Scientific Director, TIRF Technologies, United States of America
This presentation describes principles and applications of novel platform technology - TIRF-EC. Experimental data are reported that show ultimate limit of detection, simultaneous detection of multiple DNA/RNA and protein markers with no or minimum sample preparation stages. |
12:15 | Technology Spotlight |
12:30 | Lunch & Networking in Exhibition Hall |
12:45 |  Free Workshop
Single Sample, Single Slice, Single Prep, Single Well… Multiple Answers
|
13:30 | Poster Presentations |
14:15 | Sample-in Answer-out: Complex Molecular Diagnostics Assays on a Chip
Holger Becker, Chief Scientific Officer, Microfluidic ChipShop GmbH, Germany
We present strategies and examples to put complex molecular diagnostics assays including amplification steps onto microfluidic-enabled cartridges for the detection of both viral and bacterial infections. |
14:45 |  | Keynote Presentation Pharmacogenetics and Personalized Medicine: Reality vs. Hype
Wayne Grody, Professor/Co Director, University of California Los Angeles, United States of America
This presentation will highlight the many real-world considerations that must be faced in developing, validating, performing and reporting the new pharmacogenetic and genome-wide tests. Also considered will be the ethical dilemmas raised by this new technology, including genetic discrimination and privacy, level of government oversight, gene patent restrictions, and direct-to-consumer testing. |
|
15:15 | Coffee & Networking in Exhibition Hall |
16:00 | Exosomes Detection and Speciation by Nanoparticle Tracking Analysis (NTA) – Potential Biomarkers for a Broad Range of Diseases
Jeremy Warren, Chief Executive Officer, NanoSight Limited, United Kingdom
Exosomes represent a new and ubiquitous class of interacellular signalling structure and as such can be used as diagnostivc structures. NanoParticle Tracking Analysis uniquely allows for their visualisation, sizing and counting and, through the use of fluorescent labels, their phenotyping. |
16:30 | The Semiconductor Approach to Real-time, Label-free Molecular Diagnostics at the Point-of-Care
Chris Toumazou, Founder and CEO, DNA Electronics, United Kingdom
A rapid, point-of-care, system-on-chip solution for personalized medicine and infectious disease screening will be presented. This is an all-electronic, label-free, molecular diagnostic platform that digitally translates nucleic acid detection into clinically actionable information. |
17:00 | Panel Discussion: Venture Capitalists’ Best Practices on Commercializing Innovation
John Steuart, Managing Director & Co-Founder, Claremont Creek Ventures, United States of America
Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get brought to market? The panel will explore the challenges of commercialization in a still-difficult business environment. These challenges include the cost-efficient development of technology that is truly disruptive yet cost-competitive. Panelists will discuss how to best determine the size of a market and how to assess a competitive landscape. Startups that surmount these challenges then have to weigh the best route to capitalize on the investment, typically via acquisition or an IPO. While IPOs are typically most desired, VCs will discuss why acquisitions are far more common, as well as the pros and cons of guiding the development of a startup for an eventual sale.
Panelists:
Samuel Colella, Co-founder, Versant Ventures
Risa Stack, Partner, Perkins Caufield & Byers
Alexander de Winter, Partner Mohr Davidow |
18:00 | Drinks Reception |
